Friday, 19 July 2019

Dr. Reddy's announces the launch of Tobramycin Inhalation Solution

25 June 2019 | News

It is a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution

Dr. Reddy’s Laboratories has announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA). 

The TOBI® (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health.

Dr. Reddy’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 mL, single-dose Ampule. Tobi® is a trademark of Mylan.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account